-
DMD: HOPE-2 Trial Testing CAP-1002 Cleared to Continue by Board
The HOPE-2 trial has been cleared by an independent review board to resume testing CAP-1002 therapy on boys and young men with Duchenne muscular dystrophy. Read more about it here.
What do you think of this news?
Sorry, there were no replies found.
Log in to reply.